The cholesterol controversy

Annals of Pharmacotherapy

Volumn 30, Issue 5, 1996, Pages 495-499

  Geurian, Kristi L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ACCIDENT; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DEPRESSION; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; STROKE; VIOLENCE;

AGE FACTORS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; RISK FACTORS;

EID: 0029924360     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000512     Document Type: Article

References (60)

1. Brett AS. Ethical issues in risk factor intervention. Am J Med 1984;76:557-61.
2. 1992 Heart and stroke facts. Dallas: American Heart Association, 1992:199.
3. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention trial: risk factor changes and mortality results. JAMA 1982;248:1465-77.
4. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 1993;269:3015-23.
6. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentration and mortality, a quantitative review of primary prevention trials BMJ 1990;301:309-14.
7. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327:248-54,
8. Brett AS. Psychologic effects of the diagnosis and treatment of hypercholesterolemia: lessons from case studies. Am J Med 1991;91:642-7.
9. Oliver MF Might treatment of hypercholesterolemia increase non-cardiac mortality? Lancet 1991;337:1529-31.
10. Oliver MF. Reducing cholesterol does not reduce mortality. J Am Coll Cardiol 1988;12:814-7.
11. Smith GD, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
12. Oliver MF. Doubts about preventing coronary heart disease. BMJ 1992;304:393-4.
13. Jacobs DJ, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality considerations. Circulation 1992;86:1046-60.
14. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med 1993;119:136-45.
15. Barradas MA, Mikhailidis DP, Winder AF. Low serum cholesterol and suicide (letter). Lancet 1992;339:1168.
16. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990;131:579-88.
17. Cummings P, Psaty BM. The association between cholesterol and death from injury. Ann Intern Med 1994;120:848-55.
18. McKenney JM, Proctor JD, Harris S, Chinchilli VM A comparison of the efficacy and toxic effects of sustained- versus immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
19. Newman TB. Possibly disappointing results of treatment with gemfibrozil. N Engl J Med 1993;328:139-40.
20. Committee of Principal Investigators A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
21. Cutis AL, Bankhurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutary 1 coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989;8:863-9.
22. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downtown M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
23. Pierce R. FDA statement on fibric acid derivatives (letter). NIH Consensus Development Conference, Bethesda, MD, February 1992.
24. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V. Efficacy of gemfibrozil in dyslipidemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med 1993;25:41-5.
25. Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4.
26. Krumholz HM, Seeman TE, Merrill SS, Mendes de Leon CF, Vaccarino V, Silverman DI, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272:1335-40.
27. Joossens JV. Mechanisms of hypercholesterolemia and atherosclerosis. Acta Cardiologica 1988;29(suppl):63-83.
28. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic heart disease: new perspectives based on the Framingham Study. Ann Intern Med 1979;90:85-91.
29. Rossouw JE. The effects of lowering serum cholesterol on coronary heart disease risk. Med Clin North Am 1994;78:181-95.
30. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-76.
31. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
32. Scandinavian Simvastatin Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
33. Dayton S, Pearce ML, Hashmoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969;39-40(suppl II):1-63.
34. Lipid Reasearch Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
35. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
36. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
37. Trial of clofibrate in the treatment of ischemic heart disease: five year study by a group of physicians of the Newcastle-upon-Tyne region Br Med J 1971;4:767-75.
38. Ischemic heart disease: a secondary prevention trial using clofibrate: report by a research committee of the Scottish Society of Physicians Br Med J 1971;4:775-84.
39. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand 1966;466(suppl):1-92.
40. A Research Committee. Low-fat diet in myocardial infarction: a controlled trial Lancet 1965;2:501-4.
41. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report on the program on the surgical control of the hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55.
42. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-24.
43. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40
44. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.
45. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RI. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12
46. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas? Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-9.
47. Montague T, Tsuyuki R, Burton J, Williams R, Dzavik V, Koon T. Prevention and regression of coronary atherosclerosis: is it safe and efficacious therapy? Chest 1994;105:718-26.
48. Keech AC, Collins R, Peto R, Sleight P. False negative total mortality results in cholesterol-lowering trials (letter). Eur Heart J 1992;13:162.
49. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;16:112-20.
50. Canner PL, Berge KG, Wenger KK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
51. Kaplan JR, Manuck SB, Shivery C. The effects of fat and cholesterol on social behavior in monkeys. Psychosom Med 1991;53:634-42.
52. Virkkunen M, Penttinen H. Serum cholesterol in aggressive conduct disorder: a preliminary study. Biol Psychiatry 1984;19:435-9.
53. Eckernas SA, Roos BE, Kvidal P, Eriksson LO, Block GA, Neafus RP, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG-CoA reductase inhibitors in patients with primary moderate hypercholesterolemia. Br J Clin Pharmacol 1993;35:284-9.
54. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-7.
55. Glomset J, Gelb M, Farnsworth C. The prenylation of proteins, Curr Opinion Lipidol 1991;2:118-24.
56. Goldstein M. Cholesterol inhibition, cancer, and coronary heart disease (letter). Lancet 1992;340:127-8.
57. Wysowski DK, Kennedy DL, Gross TP. Prescribed use of cholesterol-lowering drugs in the US, 1978-88. JAMA 1990;263:2185-8.
58. Stehbens WE. Reduction of serum cholesterol levels and regression of atherosclerosis. Pathology 1991;23:45-53.
59. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308:373-9
60. Ravnskov U. Optimism about drug therapy is unjustified (letter). BMJ 1994;308:1038.